Data & Specimens
PIRC is able to provide longitudinal specimens and/or data to qualified investigators after review and approval of a concept proposal.
The PIRC recruits persons at risk for HIV infection to participate in regular HIV screening every 3 months. The PIRC screening program identifies up to 100 persons newly-diagnosed with HIV each year; 40% during Acute or Early stages of infection (see below). Specimens and clinical data are collected at baseline and at regular intervals thereafter (typically at weeks 2, 4, 8, 12, 24 and 48 and every 24 weeks thereafter). Participants with chronic infection are followed for 12 weeks, while participants with acute and early infection are followed for multiple years.
Stages of HIV Infection
Acute infection: HIV Ab neg/HIV-1 NAT pos (detected days to weeks following infection). Confirmed by HIV quantitative viral load and subsequent HIV Ab seroconversion.
Group IA: HIV Ab pos/HIV-1 Limiting Antigen (LAg) Avidity assay ODn (normalized optical density) ≤ 0.5 (within approximately 70 days of initial infection).
Group IB: HIV Ab pos/HIV-1 LAg ODn > 0.5 and ≤ 1.5 (greater than 70 days and less than approximately 6 months of initial infection)
Group IC: HIV Ab pos with documented negative HIV Ab within the prior 365 days
Chronic infection: HIV Ab pos/Western blot pos/HIV-1 LAg ODn > 1.5 (infection of > 6 months duration)
Age ≥16, ART-naive (≤7 days prior treatment, excluding PrEP and PEP), newly diagnosed
All PIRC participants are newly-diagnosed HIV cases who are ART-naive at study entry (excluding PrEP and PEP). All data and specimens are de-identified.
Basic medical history (co-morbid conditions), concurrent medications, co-enrollment status (primarily to ACTG studies) are also available.